Ani Pharmaceuticals Inc. (ANIP)
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
Zacks Industry Outlook Arcutis, Amicus and ANI
Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.
5 Biotech Stocks to Watch for Potential Upside
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
